PATENT CLAIM ANALYSIS

Application Number: 16248746
Application Type: Utility
Filing Date: 2019-01
Publication Date: 2019-05
Patent Classification: ["424", "001650"]

Abstract:
Described are methods and materials for use in the treatment or prophylaxis of diseases, for example cognitive disorders, using diaminophenothiazines. In particular it relates to treatments having optimised pharmacokinetic properties, and dosage forms are intended to improve the relative cognitive or CNS benefits of the diaminophenothiazines, for instance compared to haematological effects.

Claim (Index 1):
A method of treatment or prophylaxis of a cognitive or CNS disorder in a patient, wherein said disorder is one which is susceptible to treatment by a 3,7-diaminophenothiazine (DAPTZ) compound,\n which method comprises orally administering to said patient a dosage unit containing said DAPTZ compound in oxidised form as active ingredient, wherein said dosage unit releases at least 50% of said active ingredient within 30 minutes under standard US/EU Pharmacopoeia dissolution conditions.

Metadata:
- Claim Count in Document: 2.0
- Percentile: 99.0
- Lexical Diversity: 1.38095
- Patent Class: 424.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['14866035', '12681511', '12294605', '12665608', '14248730']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7880770355854985
- 35 USC 102 Novelty (BERT): 0.600069592276815
- Combined Prediction Score: 0.7692762912546302
- Mean Citation Score: 431.71220199999993
- Max Citation Score: 587.7082
- Similarity Product: 443.3083643114089

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test